In April 2022, the long-running lockdown in Shanghai, China, due to the COVID-19 pandemic led to significant restrictions on the production of iodinated contrast media (ICM) of a major supplier [1]. As other suppliers’ stocks were also becoming depleted, this resulted in a global shortage of ICM. In facilities with depleted stocks, rationing of ICM supplies could lead to reduced availability of diagnostic and interventional procedures, which is expected to last until August 2022.